Rufinamide

From Wikipedia, the free encyclopedia

Rufinamide
Systematic (IUPAC) name
1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
Identifiers
CAS number 106308-44-5
ATC code N03AF03
PubChem 129228
Chemical data
Formula C10H8F2N4O 
Mol. mass 238.194
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Rufinamide is an anticonvulsant medication.

Used in combination with other medication and therapy to treat Lennox-Gastaut syndrome and various other seizure disorders, Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

[edit] References



Languages